Sankha Bhattacharya

Sankha Bhattacharya


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
Bhagavathi Sundaram SivamaruthiBhagavathi Sundaram Sivamaruthi
Bhagavathi Sundaram Sivamaruthi
NRNeha Raghani
Neha Raghani
MCMehul R Chorawala
Mehul R Chorawala
SBSankha Bhattacharya
Sankha Bhattacharya
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
Chaiyavat ChaiyasutChaiyavat Chaiyasut
Chaiyavat Chaiyasut
The nuclear factor kappa B (NF-κB) pathway has emerged as a pivotal player in the pathogenesis of various diseases, including neurodegenerative illnesses like Alzheimer’s disease (AD). The involvement of the NF-κB pathway in immune system responses, inflammation, oxidative stress, and neuronal survival highlights its significance in AD progression. We discuss the advantages of NF-κB pathway inhibition, including the potential to mitigate neuroinflammation, modulate amyloid beta (Aβ) production, and promote neuronal survival. However, we also acknowledge the limitations and challenges associated with this approach. Balancing the fine line between dampening inflammation and preserving physiological immune responses is critical to avoid unintended consequences. This review combines current knowledge on the NF-κB pathway’s intricate involvement in AD pathogenesis, emphasizing its potential as a therapeutic target. By evaluating both advantages and limitations, we provide a holistic view of the feasibility and challenges of NF-κB pathway modulation in AD treatment. As the quest for effective AD therapies continues, an in-depth understanding of the NF-κB pathway’s multifaceted roles will guide the development of targeted interventions with the potential to improve AD management.